• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Morphic Holding Inc. (Amendment)

    2/14/24 4:15:32 PM ET
    $MORF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MORF alert in real time by email
    SC 13G/A 1 p24-0510sc13ga.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Morphic Holding, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    61775R105

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

     

     

    CUSIP No. 61775R10513G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,591,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,591,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,591,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.2%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 61775R10513G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,591,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,591,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,591,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.2%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 61775R10513G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,591,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,591,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,591,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.2%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 61775R10513G/APage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Morphic Holding, Inc. (the “Issuer”).
     
    Item 1(b). Address of Issuer's Principal Executive Offices.
      35 Gatehouse Drive, A2, Waltham, MA 02451.

     

    Item 2(a). Name of Person Filing.
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.  
      Common Stock, par value $0.0001 per share.  
         
    Item 2(e). CUSIP Number.  
      61775R105  
         
    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.
         
    Item 4. Ownership.  
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

     
    Item 5. Ownership of Five Percent or Less of a Class.  
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].  
         

     

    CUSIP No. 61775R10513G/APage 6 of 7 Pages

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 61775R10513G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      STEVEN A. COHEN
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

     

    Get the next $MORF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MORF

    DatePrice TargetRatingAnalyst
    12/8/2023$46.00Buy
    Citigroup
    9/25/2023$61.00 → $33.00Hold
    Stifel
    9/25/2023Buy → Neutral
    BTIG Research
    8/9/2023$69.00 → $61.00Buy → Hold
    Stifel
    9/7/2022$44.00Buy
    Stifel
    7/20/2022$45.00Outperform
    SVB Leerink
    3/31/2022$68.00Buy
    Canaccord Genuity
    2/25/2022$82.00 → $76.00Outperform
    RBC Capital
    More analyst ratings

    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/21/24 4:36:17 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:12:13 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:11:28 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/15/23 7:00:10 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/14/23 7:04:11 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

      Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera

      7/8/24 6:45:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Morphic Holding Inc.

      15-12G - Morphic Holding, Inc. (0001679363) (Filer)

      8/26/24 7:39:57 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:27:56 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:25:26 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Morphic with a new price target

      Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00

      12/8/23 7:51:26 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Morphic with a new price target

      Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously

      9/25/23 11:48:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic downgraded by BTIG Research

      BTIG Research downgraded Morphic from Buy to Neutral

      9/25/23 7:17:39 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Leadership Updates

    Live Leadership Updates

    See more
    • Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

      WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe

      3/19/24 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

      -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H

      2/23/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

      WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer

      5/18/22 7:30:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

      -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre

      11/3/23 7:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

      WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via

      10/9/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/12/24 9:40:06 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/7/24 7:47:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      7/8/24 10:07:20 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care